Cancer treatment-induced bone loss.
Study Goal
The researchers aimed to evaluate the role of Vitamin D supplementation in managing cancer treatment-induced bone loss (CTBL) and osteoporosis.
Results Summary
The abstract mentions that lifestyle management, including Vitamin D supplementation, is recommended for CTBL, but the supporting evidence is limited. No specific outcomes or effects of Vitamin D are detailed.
Population
Patients with cancer treatment-induced bone loss (CTBL), particularly those at heightened risk for osteoporosis.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
calcium and vitamin D supplementation | null | Cancer treatment-induced bone loss (CTBL) | null | null | is recommended | #1 |
Oral and injectable bisphosphonates | null | osteoporosis and malignant bone disease | null | null | are effective | #2 |
Bisphosphonates | increase | bone mineral density (BMD) | patients with CTBL | null | increase | #3 |
Denosumab | increase | BMD | patients in clinical trials | null | improved | #4 |
Denosumab | decrease | risk of fracture | patients in clinical trials | null | reduced | #5 |
Cancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influence quality of life. Lifestyle management, including calcium and vitamin D supplementation, is recommended but the supporting evidence is limited. Oral and injectable bisphosphonates are effective for osteoporosis and malignant bone disease. Bisphosphonates increase bone mineral density (BMD) in patients with CTBL. Denosumab is also used in the management of CTBL; in clinical trials, it improved BMD and reduced the risk of fracture. Currently, there are no bone anabolic therapies for patients with cancer. Appropriate therapies are necessary to maintain optimal bone health, particularly in patients at heightened risk.